Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2011 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Safra T, Borgato L, Nicoletto MO, Rolnitzky L, Pelles-Avraham S, Geva R, Donach ME, Curtin J, Novetsky A, Grenader T, Lai WC, Gabizon A, Boyd L, Muggia F. Safra T, et al. Among authors: donach me. Mol Cancer Ther. 2011 Oct;10(10):2000-7. doi: 10.1158/1535-7163.MCT-11-0272. Epub 2011 Aug 11. Mol Cancer Ther. 2011. PMID: 21835933 Free article.
Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
Nicoletto MO, Dalla Palma M, Donach ME, Gusella M, Cappetta A, Shams M, Marchet A, Nardin M, Pintacuda G, Di Maggio A, Marchesi M, Carli P, Fiduccia P, Artioli G, Nitti D. Nicoletto MO, et al. Among authors: donach me. Tumori. 2010 Nov-Dec;96(6):918-25. Tumori. 2010. PMID: 21388052
Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer.
Nicoletto MO, Bertorelle R, Borgato L, De Salvo GL, Artioli G, Lombardi G, Zustovich F, Marcato R, Parenti A, Montagna M, Donach ME. Nicoletto MO, et al. Among authors: donach me. Int J Gynecol Cancer. 2009 Aug;19(6):1022-8. doi: 10.1111/IGC.0b013e3181a83cb5. Int J Gynecol Cancer. 2009. PMID: 19820363 Clinical Trial.